[EN] FUSED HETEROCYCLIC OR CARBOCYCLIC COMPOUNDS CARRYING A SUBSTITUTED CYCLOALIPHATIC RADICAL AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES [FR] COMPOSÉS HÉTÉROCYCLIQUES OU CARBOCYCLIQUES CONDENSÉS PORTANT UN RADICAL CYCLOALIPHATIQUE SUBSTITUÉ ET LEUR UTILISATION POUR TRAITER LES MALADIES LIÉES À LA VASOPRESSINE
[EN] FUSED HETEROCYCLIC OR CARBOCYCLIC COMPOUNDS CARRYING A SUBSTITUTED CYCLOALIPHATIC RADICAL AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES [FR] COMPOSÉS HÉTÉROCYCLIQUES OU CARBOCYCLIQUES CONDENSÉS PORTANT UN RADICAL CYCLOALIPHATIQUE SUBSTITUÉ ET LEUR UTILISATION POUR TRAITER LES MALADIES LIÉES À LA VASOPRESSINE
[EN] N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE À LIAISON N, UTILES COMME AGENTS ANTIBACTÉRIENS
申请人:PFIZER
公开号:WO2011073845A1
公开(公告)日:2011-06-23
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).
A new rearrangement reaction of spirocyclic cyclobutane N-halo aminals is described. This process, promoted by treatment of the aminals with N-halosuccinimides (NXS, X = Br or Cl), efficiently produces bicyclic amidines by a pathway involving initial N-halogenation of one of the aminal nitrogens followed by cyclobutane ringexpansion through 1,2-C-to-N migration with simultaneous N–X bond cleavage
N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
申请人:Brown Matthew Frank
公开号:US20120258948A1
公开(公告)日:2012-10-11
The present invention is directed to a new class of hydroxamic acid derivatives of formula I,
wherein the variables G, T, D, L, R
1
, R
2
, R
3
are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.
N-linked hydroxamic acid derivatives useful as antibacterial agents
申请人:Brown Matthew Frank
公开号:US08664401B2
公开(公告)日:2014-03-04
The present invention is directed to a new class of hydroxamic acid derivatives of formula I,
wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.
N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents
申请人:Pfizer Inc.
公开号:US20140128363A1
公开(公告)日:2014-05-08
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.